# Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas

> **NCT03586024** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Abramson Cancer Center at Penn Medicine**

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03586024
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-03-12
- **Primary completion:** 2020-08-19
- **Final completion:** 2020-08-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** poor accrual
- **Last updated:** 2021-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03586024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03586024, "Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03586024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*